高级搜索
肝细胞性肝癌合并门静脉高压症的外科治疗[J]. 肿瘤防治研究, 2014, 41(08): 925-927. DOI: 10.3971/j.issn.1000-8578.2014.08.015
引用本文: 肝细胞性肝癌合并门静脉高压症的外科治疗[J]. 肿瘤防治研究, 2014, 41(08): 925-927. DOI: 10.3971/j.issn.1000-8578.2014.08.015
Surgical Treatment of Hepatocellular Carcinoma with Portal Hypertension[J]. Cancer Research on Prevention and Treatment, 2014, 41(08): 925-927. DOI: 10.3971/j.issn.1000-8578.2014.08.015
Citation: Surgical Treatment of Hepatocellular Carcinoma with Portal Hypertension[J]. Cancer Research on Prevention and Treatment, 2014, 41(08): 925-927. DOI: 10.3971/j.issn.1000-8578.2014.08.015

肝细胞性肝癌合并门静脉高压症的外科治疗

Surgical Treatment of Hepatocellular Carcinoma with Portal Hypertension

  • 摘要: 目的 探讨肝细胞性肝癌合并门静脉高压症一期联合手术治疗的可行性。方法 回顾性分析56例肝细胞性肝癌合并门静脉高压症施行手术治疗的患者,其中37例行单纯脾切除术,19例附加贲门周围血管离断术。42例行部分肝切除,其中2例联合术中射频消融,10例行规则性左外肝切除术,单纯术中肝癌射频消融4例。结果 本组手术过程顺利,无手术死亡。术后并发症包括:门静脉血栓形成(PVT) 16例、腹腔感染1例、胸腔积液15例、腹水9例、急性炎症反应综合征1例、术后进食困难1例、腹腔大量渗血1例、切口感染3例、肺部感染2例。随访48例,肝功能明显改善,1年内死亡8例,生存率83.3%(40/48); 3年内死亡20例,生存率58.3%(28/48),其中死于肝癌复发或转移18例、死于上消化道出血1例、意外死亡1例。结论 肝细胞性肝癌合并门静脉高压症一期联合手术治疗不增加手术死亡率,施行联合手术是安全可行的。

     

    Abstract: Objective To explore the feasibility of one-stage combined surgery for hepatocellular carcinoma (HCC) with portal hypertension (PHT). Methods A total of 56 patients with HCC and PHT underwent surgery were retrospectively analyzed. Thirty-seven cases only received splenectomy, and 19 cases received splenectomy, and pericardial blood vessel disarticulation. Fourty-two patients underwent partial hepatectomy, of which 2 cases combined with intraoperative radiofrequency ablation (RFA), 10 cases underwent regular left lateral hepatic resection and 4 cases received intraoperative RFA only. Results The surgery went smoothly with no death during the operation. The postoperative complications were 16 patients suffered from portal vein thrombosis (PVT), 1 patient experienced abdominal infection, 15 patients had pleural effusion, 9 patients had ascites, 1 patient had acute inflammatory response syndrom, 1 patient had difficulty in eating, 1 patient experienced abdominal mass oozing of blood, 3 patients suffered from wound infection and 2 patients suffered from pulmonary infection. There were 48 patients being followed up. And the liver funtion was improved significantly. Eight patients died within one year and the survival rate was 83.3% (40/48). During 3-year period, 20 patients died and the survival rate was 58.3% (28/48), of which 18 patients died of tumor recurrence or metastasis, 1 patient died of postoperative upper gastrointestinal hemorrhage and 1 patient had accidental death. Conclusion One-stage combined surgery doesn't increase the opeative mortality rate in the treatment of HCC with PHT, suggesting that it is a safe and feasible method.

     

/

返回文章
返回